A Phase 1b/2 trial of TAS1440 for the treatment of myeloproliferative neoplasms
Latest Information Update: 04 Nov 2025
At a glance
- Drugs TAS 1440 (Primary)
- Indications Myeloproliferative disorders
- Focus Adverse reactions
Most Recent Events
- 04 Nov 2025 New trial record